Holen Sie sich die Stockscreener-App
90.14
1.36%
1.21
Blueprint Medicines Corp Aktie (BPMC) Neueste Nachrichten
Blueprint Medicines director Jeffrey Albers sells $1.35 million in stock - Investing.com India
Blueprint Medicines COO Christina Rossi sells $218,098 in shares By Investing.com - Investing.com Australia
Blueprint Medicines COO Christina Rossi sells $218,098 in shares - Investing.com
Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC) - GuruFocus.com
Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers Sells 15,000 Shares - MarketBeat
Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares of Stock - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Shares Down 3.6%What's Next? - MarketBeat
Blueprint Medicines Corporation Seeks Validation of 2024 Stockholder Actions Through Section 205 Action - Defense World
Blueprint Medicines' SWOT analysis: stock's potential in precision oncology - Investing.com
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
Geode Capital Management LLC Raises Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $169,639.94 in Stock - MarketBeat
Blueprint Medicines officer sells shares worth $169,635 - Investing.com
Blueprint Medicines officer sells shares worth $169,635 By Investing.com - Investing.com UK
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Barclays PLC - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short Interest - MarketBeat
Blueprint Medicines' SWOT analysis: stock outlook amid Ayvakit success - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by State Street Corp - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zimmer Partners LP Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Castleark Management LLC - MarketBeat
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting - Quantisnow
Holocene Advisors LP Sells 926,550 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Blueprint Medicines (FRA:2L9) Profitability Rank : 3 (As of Sep. 2024) - GuruFocus.com
Jacobs Levy Equity Management Inc. Buys 306,079 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines CEO Kate Haviland sells $227,304 in shares By Investing.com - Investing.com Australia
Blueprint Medicines CEO Kate Haviland sells $227,304 in shares - Investing.com
Erste Asset Management GmbH Purchases New Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Short Interest Down 5.3% in November - MarketBeat
The Manufacturers Life Insurance Company Has $13.88 Million Stake in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by Edgestream Partners L.P. - MarketBeat
Fred Alger Management LLC Sells 15,478 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Sells 316,913 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 5,132 Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Eventide Asset Management LLC Grows Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Alkeon Capital Management LLC Has $66.50 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Citigroup Inc. - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Ally Bridge Group NY LLC - MarketBeat
Intech Investment Management LLC Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Massachusetts Financial Services Co. MA Has $23.33 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Pitcairn Co. Has $954,000 Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Acquires New Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (FRA:2L9) EPS without NRI : €-4.43 (TTM As of Sep. 2024) - GuruFocus.com
Blueprint Medicines (FRA:2L9) Revenue per Share : €6.33 (TTM As of Sep. 2024) - GuruFocus.com
Blueprint Medicines (FRA:2L9) Operating Cash Flow per Share : €-3.56 (TTM As of Sep. 2024) - GuruFocus.com
Algert Global LLC Purchases 26,696 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Eagle Asset Management Inc. - MarketBeat
Blueprint Medicines director Coats sells $1.87 million in stock - Investing.com India
Principal Financial Group Inc. Sells 47,153 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines director Coats sells $1.87 million in stock By Investing.com - Investing.com Canada
What is Zacks Research's Forecast for BPMC FY2024 Earnings? - MarketBeat
Segall Bryant & Hamill LLC Buys 14,668 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (LTS:0HOJ) Enterprise Value : $5,746.9 Mil (As of Nov. 20, 2024) - GuruFocus.com
Blueprint Medicines initiated with an Overweight at JPMorgan - MSN
Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Cut by Victory Capital Management Inc. - MarketBeat
JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):